Last reviewed · How we verify
Ro 65-5788 (Ceftobiprole medocaril)
Ceftobiprole medocaril works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
Ceftobiprole medocaril is a small molecule antibiotic in the ceftobiprole class, originally developed by Advanz Pharma and currently owned by Istx. It is used to treat infections of the skin and/or subcutaneous tissue. Ceftobiprole medocaril is off-patent, meaning it is no longer protected by active patents. It is not clear if it has been approved by the FDA. As an off-patent medication, it may be available from generic manufacturers.
At a glance
| Generic name | Ceftobiprole medocaril |
|---|---|
| Also known as | ceftobiprole |
| Sponsor | Advanz |
| Drug class | ceftobiprole medocaril |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | discontinued |
Mechanism of action
Imagine your body's cells are like buildings, and bacteria are like construction workers. Ceftobiprole medocaril stops the bacteria from building new walls around themselves, which is essential for their survival. Without these walls, the bacteria can't function properly and eventually die.
Approved indications
- Infection of skin AND/OR subcutaneous tissue
Common side effects
Key clinical trials
- Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations
- Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation. (NA)
- Pathogenicity Factors of Staphylococcus Pettenkoferi in Foot Wounds and Osteitis in Diabetic Patients
- Individualized Precision Therapy With Ceftobiprole Guided by PK/PD in Geriatric Populations
- Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age (PHASE3)
- Impact of Three Probabilistic Antibiotic Therapy on Digestive Microbiota and Colonization With Multi-resistant Bacteria (NA)
- A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin (PHASE1)
- Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ro 65-5788 CI brief — competitive landscape report
- Ro 65-5788 updates RSS · CI watch RSS
- Advanz portfolio CI